Human genome sciences announces resubmission of raxibacumab bla to FDA

Human Genome Sciences, 07/11/2012

Human Genome Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax, and has established December 2012 as the Prescription Drug User Fee Act (PDUFA) action date.

Print Article Summary Cat 2 CME Report